PTAB Allows Amendments To Jevtana Patent On Remand
The Patent Trial and Appeal Board on Tuesday allowed Sanofi to amend a patent covering its prostate cancer drug Jevtana, finding that Mylan had not shown the substitute claims are unpatentable....To view the full article, register now.
Already a subscriber? Click here to view full article